Table 3 |
||||||
|
Odds ratios and 95% confidence intervals for associations of SULT1A1 and UGT1A1 genotypes with breast cancer phenotypes |
||||||
|
Phenotype |
Genotype [number (%) of subjects] |
Adjusted odds ratio |
Adjusted 95% confidence interval |
P |
||
|
|
||||||
|
High-activity SULT1A1 genotypea |
Other SULT1A1 genotypes |
|||||
|
|
||||||
|
Age at diagnosis |
<60 years |
57 (66.28%) |
48 (53.33%) |
1.85d |
1.00–3.45d |
0.08 |
|
≥60 years |
29 (33.72%) |
42 (46.67%) |
||||
|
Tumor size |
≤2 cm |
54 (71.05%) |
33(51.56%) |
2.63e |
1.25–5.56e |
0.02 |
|
>2 cm |
22 (28.95%) |
31 (48.44%) |
||||
|
Tumor grade |
1 |
20 (25.32%) |
16 (22.86%) |
|||
|
2 or 3 |
59 (74.68%) |
54 (77.14%) |
1.36e |
0.52–2.50e |
0.73 |
|
|
|
||||||
|
Low-activity UGT1A1 genotypesb |
Other UGT1A1 genotypes |
|||||
|
|
||||||
|
Age at diagnosis |
<60 years |
6 (31.58%) |
112 (61.88%) |
|||
|
≥60 years |
13 (68.42%) |
69 (38.12%) |
3.70d |
1.33–10.00d |
0.01 |
|
|
Tumor size |
≤2 cm |
12 (70.59%) |
86 (61.87%) |
1.42e |
0.45–4.44e |
0.48 |
|
>2 cm |
5 (29.41%) |
53 (38.13%) |
||||
|
Tumor grade |
1 |
4 (21.05%) |
40 (26.85%) |
|||
|
2 or 3 |
15 (78.95%) |
109 (73.15%) |
3.70e |
1.33–10.00e |
0.59 |
|
|
|
||||||
|
SULT1A1 and UGT1A1 high-activity genotypesc |
Other SULT1A1 and UGT1A1 genotypes |
|||||
|
|
||||||
|
Age at diagnosis |
<60 years |
20 (57.14%) |
82 (59.85%) |
1.10d |
0.52–2.35d |
0.77 |
|
≥60 years |
15 (42.86%) |
55 (40.15%) |
||||
|
Tumor size |
≤2 cm |
19 (70.37%) |
67 (59.82%) |
1.79e |
0.69–4.55e |
0.31 |
|
>2 cm |
8 (29.63%) |
45 (40.18%) |
||||
|
Tumor grade |
1 |
11 (37.93%) |
24 (20.51%) |
2.56e |
1.04–6.25e |
0.05 |
|
2 or 3 |
18 (62.07%) |
93 (79.49%) |
||||
|
|
||||||
|
Associations in the group of ER-negative tumorsf |
High-activity SULT1A1 genotypea |
Other SULT1A1 genotypes |
||||
|
|
||||||
|
Age at diagnosis |
<60 years |
21 (91.30%) |
12 (60.00%) |
7.14d |
1.23–50d |
0.02 |
|
≥60 years |
2 (8.70%) |
8 (40.00%) |
||||
|
Tumor size |
≤2 cm |
18 (78.26%) |
7 (41.18%) |
14.28e |
2.17–100e |
0.02 |
|
>2 cm |
5 (21.74%) |
10 (58.82%) |
||||
|
|
||||||
|
SULT1A1 and UGT1A1 high-activity genotypesc |
Other SULT1A1 and UGT1A1 genotypes |
|||||
|
|
||||||
|
Tumor size |
≤2 cm |
22 (73.33%) |
3 (30.00%) |
9.02e |
1.59–51.31e |
0.01 |
|
>2 cm |
8 (26.67%) |
7 (70.00%) |
||||
|
Tumor grade |
1 |
3 (37.50%) |
3 (8.82%) |
10.00e |
1.09–100e |
0.04 |
|
2 or 3 |
5 (62.50%) |
31 (91.18%) |
||||
|
|
||||||
|
Associations in the group of ER-positive tumorsf |
Low-activity UGT1A1 genotypesb |
Other UGT1A1 genotypes |
||||
|
|
||||||
|
Age at diagnosis |
<60 years |
1 (14.29%) |
47 (60.26%) |
|||
|
≥60 years |
6 (85.71%) |
31 (39.74%) |
9.09d |
1.08–100d |
0.02 |
|
|
|
||||||
|
Statistically significant P values, as determined by the chi-squared test, are indicated in bold. ER, estrogen receptor. aHigh-activity SULT1A1 genotype, SULT1A1*1/*1. bLow-activity UGT1A1 genotypes, UGT1A1*28/*28 and UGT1A1*28/*34. cHigh-activity UGT1A1 genotypes, UGT1A1*1/*1, UGT1A1*33/*33 and UGT1A1*1/*33. dAdjusted for race (Caucasian or not Caucasian). eAdjusted for age at diagnosis and race (Caucasian or not Caucasian). fOnly statistically significant associations are shown. |
||||||
|
Shatalova et al. Breast Cancer Research 2005 7:R909 doi:10.1186/bcr1318 |
||||||
